-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, U9gi0+JjOrYwi4uQYni58H8fy1ROiojpXqmto+X7neiKQlYclAtoZj/zJgljQhj9 f+tdFjm166q6qoBS87T8dA== 0000914260-07-000205.txt : 20071121 0000914260-07-000205.hdr.sgml : 20071121 20071121092120 ACCESSION NUMBER: 0000914260-07-000205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20071120 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20071121 DATE AS OF CHANGE: 20071121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRO MED INC /NEW/ CENTRAL INDEX KEY: 0000008146 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 050318215 STATE OF INCORPORATION: RI FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13200 FILM NUMBER: 071261562 BUSINESS ADDRESS: STREET 1: 600 E GREENWICH AVE CITY: WEST WARWICK STATE: RI ZIP: 02893 BUSINESS PHONE: 4018284000 MAIL ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 FORMER COMPANY: FORMER CONFORMED NAME: ATLAN TOL INDUSTRIES INC DATE OF NAME CHANGE: 19850220 8-K 1 form8k1120.htm FORM 8-K

 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K


 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT

(DATE OF EARLIEST EVENT REPORTED)

November 20, 2007


ASTRO-MED, INC

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


COMMISSION FILE NUMBER             0-13200

RHODE ISLAND

05-0318215

(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

(IRS EMPLOYER IDENTIFICATION NUMBER)

 

 

 

600 EAST GREENWICH AVENUE, WEST WARWICK, RI 02893

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)

(401-828-4000)

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

 


 

 

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 20, 2007, Astro-Med, Inc. (the “Company”) issued a press release in which it disclosed unaudited financial information related to third quarter consolidated earnings. A copy of the press release relating to such announcement, dated November 20, 2007, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(c)

Exhibit

Exhibit no.

Exhibit

99.1

Press Release dated November 20, 2007

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

 

DATE: November 20, 2007

ASTRO-MED, INC.

 

 

 

By: /s/ Joseph P. O’Connell

 

________________________

Joseph P. O’Connell

Vice President, Treasurer and Chief Financial Officer

 

INDEX TO EXHIBITS

 

 

 

Exhibit No.

Exhibit

 

99.1

Press Release Dated November 20, 2007

 

 

EX-99 2 pressrelease1120.htm PRESS RELEASE

Exhibit 99.1

 

PRESS RELEASE

 


 

600 East Greenwich Avenue

West Warwick, Rhode Island 02893

 

For Immediate Release

November 20, 2007

 

Contact: Albert W. Ondis

 

Joseph P. O’Connell

 

Astro-Med, Inc.

 

(401) 828-4000

 

www.astro-medinc.com

 

Astro-Med Reports Record Sales in Third Quarter;

Directors Declare Regular Dividend

 

West Warwick, RI, November 20, 2007 -- Astro-Med, Inc. (NASDAQ:ALOT) reports record sales for the Third Quarter of $19,139,000, representing an increase of 19% over the $16,043,000 achieved in the Third Quarter of the prior fiscal year. Third Quarter bookings amounted to a record $21,000,000.

 

Net Income in the current quarter is $1,562,000 or $0.21 per diluted share, compared to $3,977,000, or $0.53 per diluted share in the prior year. Excluding the gain on the sale of real estate in the prior year, net income increased 91% or $0.10 per diluted share over the Third Quarter of the prior fiscal year. Favorable changes in foreign currency rates added approximately $351,000, representing about 2% of the current quarter’s sales.

 

Net Income in the current quarter includes expenses of approximately $131,000 after tax, equal to $0.02 per diluted share for stock-based compensation as well as tax benefits of approximately $446,000, or $0.06 per diluted share, due to favorable resolution of certain income tax examinations. Net income in the previous year fiscal quarter included an expense of approximately $93,000, after tax, equal to $.01 per diluted share, for stock-based compensation as well as a tax benefit of $231,000, or $.03 per diluted share, due to favorable adjustments identified in the filing of the prior year tax return.

 

For the nine-month period ended November 3, 2007, the Company reports net sales of $54,241,000, an increase of 13% over the $47,951,000 reported in the same period of the prior fiscal year. For the nine-month period of the current fiscal year, net income is $2,969,000, equal to $0.39 per diluted share. Net income for the nine-month period includes an expense of approximately $365,000, after tax, equal to $0.05 per diluted share, for stock-based compensation as well as $446,000, or $0.06 per diluted share, related to the tax benefits noted above. Favorable changes in foreign currency rates added approximately $828,000, representing about 2% to sales for the nine-month period.

 

 

2

 

 

For the corresponding period of the prior year, the Company reported net income of $5,260,000, equal to $0.71 per diluted share. Excluding the real estate related gain,

earnings were $2,135,000, equal to $0.29 per diluted share. Net income for the nine- month period includes expense of $266,000 after tax, equal to $0.04 per diluted share, for stock based compensation, as well as $231,000 or $0.03 per diluted share, related to favorable tax adjustments noted above.

 

Comments from CEO

 

Commenting on the results, Albert W. Ondis, Chief Executive Officer stated: “We are pleased to report another strong quarter of sales growth and improved profitability at Astro-Med. Sales of QuickLabel Systems Products increased 28% from the prior year, Test & Measurement Products sales increased 15% over the previous year, while Grass Technologies sales rose 7% from the prior year.

 

“The Company’s gross profit margin improved to 43.7% from the prior year’s 40.1% while operating income reached $1,738,000 in the quarter, a 177% improvement over the prior year’s operating income of $628,000, excluding the $5,252,000 one time gain we realized from the sale of the Company’s excess real estate.

 

“Our backlog rose 17% to $8,027,000 during the quarter, achieved through record new order bookings of $21,000,000. Our balance sheet remains healthy with an increase in the Company’s cash and related securities to $17,213,000 during the quarter. The Company’s current ratio stands at 5:44 at the end of the quarter, with no debt and operations that generated approximately $5,000,000 in EBITDA through the first nine months.”

 

Directors Declare Regular Dividend

 

On November 19, 2007, the Directors of Astro-Med declared the regular quarterly cash dividend of $0.05 per share payable on January 2, 2008 to shareholders of record on December 14, 2007. The Company expects to maintain the cash dividend rate of $0.20 per share.

 

Third Quarter Conference Call Scheduled November 21, 2007

 

The Third Quarter conference call will be held on Wednesday, November 21, 2007 at 11:00 AM EST. It will be broadcast in real time on the Internet through the Investor Relations portion of our website at www.astro-medinc.com. We invite you to log on and listen in on November 21st, or access the broadcast any time for up to 5 days following the event.

 

 

 

 

 

 

3

 

 

ASTRO-MED, INC.

 

Consolidated Statement of Operations

In Thousands Except for Per Share Data

(Unaudited)

 

 

Three-Months Ended

 

Nine-Months Ended

 

 

November 3, 2007

 

October 28, 2006

 

November 3, 2007

 

October 28, 2006

 

Net Sales

$19,139

 

$16,043

 

$54,241

 

$47,951

 

 

 

 

 

 

 

 

 

 

Gross Profit

8,372

 

6,427

 

$23,049

 

19,699

 

 

43.7%

 

40.1%

 

42.5%

 

41.1%

 

Operating Expenses:

 

 

 

 

 

 

 

 

Selling, General & Administrative

5,450

 

4,819

 

16,010

 

14,365

 

Research & Development

1,184

 

980

 

3,417

 

2,977

 

 

6,634

 

5,799

 

19,427

 

17,342

 

 

 

 

 

 

 

 

 

 

Gain on Sale of Real Estate, Net

--

 

5,252

 

--

 

5,252

 

 

 

 

 

 

 

 

 

 

Operating Income

1,738

 

5,880

 

3,622

 

7,609

 

 

9.1%

 

36.6%

 

6.7%

 

15.9%

 

 

 

 

 

 

 

 

 

 

Other Income, Net

170

 

348

 

632

 

689

 

 

 

 

 

 

 

 

 

 

Income Before Taxes

1,908

 

6,228

 

4,254

 

8,298

 

 

 

 

 

 

 

 

 

 

Income Tax (Provision)

(346)

 

(2,251)

 

(1,285)

 

(3,038)

 

 

 

 

 

 

 

 

 

 

Net Income

$1,562

 

$3,977

 

$2,969

 

$5,260

 

 

 

 

 

 

 

 

 

 

Net Income Per Share – Basic

$ 0.23

 

$ 0.59

 

$ 0.43

 

$ 0.78

 

Net Income Per Share – Diluted

$ 0.21

 

$ 0.53

 

$ 0.39

 

$ 0.71

 

 

 

 

 

 

 

 

 

 

Weighted Average Number of Common Shares - Basic

 

6,912

 

 

6,693

 

 

6,881

 

 

6,712

 

Weighted Average Number of Common Shares - Diluted

 

7,510

 

 

7,439

 

 

7,552

 

 

7,379

 

 

 

 

 

 

 

 

 

 

Dividends Declared Per Common Share

 

$0.05

 

 

$ 0.05

 

 

$0.15

 

 

$0.15

 

 

Selected Balance Sheet Data

In Thousands (Unaudited)

 

 

 

 

As of

November 3, 2007

 

As of

January 31,  

2007

Cash & Marketable Securities

$17,213

$20,130

 

 

 

Current Assets

$46,671

$44,168

 

 

 

Total Assets

$60,117

$58,001

 

 

 

Current Liabilities

$8,577

$9,874

 

 

 

 

 

4

 

 

Shareholders’ Equity

 

 

$48,386

$45,958

 

Reconciliation of Non-GAAP Financial Information

 

In an effort to provide investors information regarding the Company’s results, the Company disclosed certain Non-GAAP information which management believes provides useful information to the investor.

 

A reconciliation of net income and net income per diluted share as reported under GAAP to the pro forma net income and pro forma net income per diluted share excluding the gain related to the sale of certain real estate and the favorable tax adjustments for the three-months and nine-months ended November 3, 2007 and October 28, 2006 is as follows:

 

 

 

Three-Months Ended

Nine-Months Ended

 

11/3/2007

10/28/2006

11/3/2007

10/28/2006

Operating Income- GAAP

$1,738

$5,880

$3,622

$7,609

Less Real Estate Transaction

_

(5,252)

_

(5,252)

Operating Income – Proforma

1,738

628

3,622

2,357

Other Income, Net

170

348

632

689

Income Tax Benefit

446

231

446

231

Income Tax Provision

(1,238)

(586)

(2,177)

(1,373)

Net Income Proforma

$1,116

$621

$2,523

$1,904

EPS Per Share – Diluted - Proforma

$0.15

$0.08

$0.33

$0.26

 

 

About Astro-Med, Inc.

 

Astro-Med, Inc. is a leading manufacturer of high tech specialty printing systems, electronic medical instrumentation, and test and measurement instruments sold under the brand names Astro-Med®, Grass® Technologies and QuickLabel® Systems. Astro-Med Inc. products are employed around the world in a wide range of industrial, scientific, and medical applications. Additional information about Astro-Med, Inc. is available by visiting www.astro-medinc.com.

 

Safe Harbor Statement

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med’s FY2007 annual report and its annual and quarterly filings with the Securities and Exchange Commission.

 

 

GRAPHIC 3 img1.gif GRAPHIC begin 644 img1.gif M1TE&.#=A70$H`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P` M````70$H`(<````8&!@7%Q<6%A8='1T-#0T"`@('!P<1$1$!`0$.#@X/#P\, M#`P5%140$!`3$Q,*"@H("`@$!`0&!@84%!0)"0D:&AH<'!P2$A(%!04?'Q\+ M"PL;&QL#`P,>'AX9&1DV-C8P,#`K*RLM+2TL+"PC(R,B(B(I*2DT-#0^/CX@ M("`S,S,\/#PN+BXU-34W-S7EY`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`@,!`@,!`@,(_P#Y"1Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS( ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZES9S9O/GT"#"AU* MM"C0;SN3*IT([@<``%Z6?O3TM*K5JUBS:MV:%<0GJ6##$O0%X(NW7T``A!.+ M41S7MV]#?`%#MZ[=NW2_!`#@AZ,($2-&D"BQEBU&/R8"*Q8PSB"Y$B04CQA0 MCN2`P"=0"#0'X!RH4'_"`0,`$5#B$01$&8;+&FL!=!9):QR%-9AAC$&R-BY( M*BLYDE9_"`0@[)=5?F%2/#1@M11;4ZVC/PUTL808C4*P#ON8SNJIFP>R%O\F MF!4!25164_%SRX^8[/0>MD)01)JEAE##^F#,'/:$"LP(!`!K#34#M7&68&5RD4<%4#![E3 MXD4#9J1`5F=\]&)-[VC%H`-9]342&L?Q!$R6H'Q$7-/+7"3BP\.-%I6)4$0)#^D)4-:.A'P0Z)#A%C% M"I1;*2,/E59B*2"!%TF@594-_;*,&FH4M]`$5;7B$#)&@)(0,\V`L88KOUS4 M6U4S/A7@?V@BA$XA]@'`1C$--=.&@VZT,UQ51PS_U((AW?$3(3\NO.$0'`L6 M%(PSS@PSCT"O&/$4$O$P1,\A#U3UG4UD)`Z/&9U04?19H6!0-E1 MRT]0WT"#K43:3D0/`<>=,%]"T8"I51,%;24!08Q6Q6953A0$#LU;Q3J1H$_% MH$A5XRU2E3U6R6$0+&_M5E`L6F7`[5-S$!2."58]\1`]5K5+D"Q6M=%L5HP< MA(]\6T'!4E4SI`&&&E?909Y6;%ROE2\$ MJ0A7!1(Y8Y4H=W@^K1216$5-031<5<,26!FD(&M3;,1V59(4)`=6+*0!.K9T MN$H2TM"$JV0N([I;$S^(4)4!'$0=Q(.(\1XB"JNX02!3JLHD#H*VJ@B`(+"K MR@EL5Q5*&,1`6*&"%*KP&X%8(6W5$,@[0!#!A-CB.&PPWRVJ@HXU6$4>!,'# M5?\6QX\,6"4:!+'&55:1#X$(0F<`*)I&G&"5&A'D"E:A`"X&<@T_*>QF`J'; M4UZQD00^Q08$X=M3"%60*RGP3Q79P)KT894_'(1+5;E!SQI8$.-4Q1T&,<95 M@`#(@C2I*E;0QQZKPHR(V.$X:3#?"IXR`WX,H"HX6.13D#*0V55E#0/YQE4V M2!`*6$49&[F*>@@2GJH@<2#8L,H(M?>4;A`D%U910QFU`HE%LI$@;DS>WP`E M$1]6I1(#Z0XF#_*\JGR!%`VQA%6:6)#.5:4*")F!50XXD"]8Q1D#*88H2$'. M0$+XE%44Q&55N:!`O&'_%?`5A!%OM,@PL&65 MAPTD&%:1HD"X5A7E%*0%4YB""Y"QRZPHDB`U6&.?`@HS8D;$3Y![2@@.HHRL M1``+GE`(%9_BSX)<@J/3>LI!_`4`<`HD7?&C91[XH$I<6*'54Q!D/T] MQ0!L@()2E4K3Y@G$#U:!AD'T(,*-;.HI42$(/*SBBH*([X\$"855,&$2,_IM M(&K\Y4""*5,8>90?RD#E0E)AE2V6LBJH,P@^ZR:.U%6%`P=I057,A4Q0@% MZ2D`B"B0/[SQ!C#]B!D5>CVU_PJ$K6>%HT!^J@#YY"\A5YF``1)`W`X0;T]O M89#@JK('OSY%0P=)@E4N6I"@/64?`B%15LI`$,,FCUXR!14`M,$/2;Q1.A<2 MR&:?4H.#:*$J4=@(%MI6D%:VE2![J$J2:)G5DIAU*[;E!VXQHB4KY&`@WIC` M6P<"".ETUB#Y<`17;%$06EA%GK>L8N)@:I4X"02@60G;0"J4O"[*%+8`T(%` M)B=,?NS#*C?PPR!F3&,:2VP@&7V*(IP+@$QL),=/<1TK`UJ'9=+R"RQID!]+1A$+080T+>,\JS24(_$)G M$/$"P/\:"&':?0FR!:N0DA_ZB$<]]LSG?5!3($>H2NVR416L!1G/5ME!&H_X M$"##P2"NKSQ`]I6B3@_[O>4=/.#Q$__^>U`8@"8$4"@ M($#.;1^NLNN!+.,"@2G!@A6BQJ< M"7&$`3;J[N(Q@AI1\H/")R#(&GY*T+"@"6WO'%?+I#W5H5WM(R`+`2R#@]8A04%T695#G"A<]#=*K,F MB#3A"Q&R5<4Y!,&[;9>7=JO`0!_H>"$8U1V'B60BIPBY%M6?@KN*E$`/^""` MUDGSBI'Q(P$!N@HG#9*Q\UZE"5.@0K>?4G1:/H7:M-2%0EJS<8@$D,U[MXK% M8EH[@O0`+C$P2+&Y\G."K/0I68!(_TB?\NV!?*`JMB>(#.IE$'R]Q%=*5<0G&`52&80O+`5#T80%F`5 M8C@1#=:#CO_(&@1Q(I0P#A`($A`VAT$9"P"(5PC_B8C_JXC_RX"(GPCP`9 MD`(9D(1@$,6``AG0`50@54A'#[G6>@GQ#@_YA`DQ"?8X"`R2$+G60@0AD13I M$.0P"(8@9#GAD!_I$.APD@Q!-GIS&R[YDC`I%:H8DS19DS:I$N$Q<'Y8<),\ MV9,^Z1%*,",E0!\_691&>90,<2T`H#9(V91.B92>$`0F])146956690!`0`[ ` end
-----END PRIVACY-ENHANCED MESSAGE-----